Therefore, on the basis of PD-L1 inhibitors combined with chemotherapy, whether TRT can further improve the efficacy of patients with ES-SCLC has an emerging research topic; however, effective clinical evidence is still lacking. This evidence concerns the gene CD274 and small cell lung carcinoma.